Gene therapy strategies for the treatment of chronic viral hepatitis

Expert Opinion on Biological Therapy

Volumn 1, Issue 4, 2001, Pages 629-639

  Chiou, Henry C ^a   Lucas, Michael A ^a   Coffin, Christopher C ^a   Banaszczyk, Mariusz G ^a   Charles, R ^a   Lollo, Charles P ^a  

^a Orchestra Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; POLYMER; RECOMBINANT PROTEIN;

ANIMAL; CHEMISTRY; CHRONIC DISEASE; DNA VECTOR; GENE THERAPY; GENE TRANSFER; GENETICS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; LIVER; METABOLISM; METHODOLOGY; MOUSE; PHYSIOLOGY; REVIEW; VIROLOGY; VIRUS HEPATITIS;

ANIMAL; CHRONIC DISEASE; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS, VIRAL, HUMAN; HUMAN; INTERFERON-ALPHA; LIVER; MICE; POLYMERS; RECOMBINANT PROTEINS;

EID: 0035405514     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.4.629     Document Type: Article

References (85)

1. WARRIER I, EWENSTEIN BM, KOERPER MA etaL: Factor DC inhibitors and anaphylaxis in hemophilia B.J. Pedtntr. HematoL OncoL (1997) 19:23-27.
2. HOYER LW: Factor VIII inhibitors. Curr. Of in. HematoL (1995) 2:365-371.
3. ANTONELLI G: Development of neutralizing and binding antibodies to Interferon (IFN) in patients undergoing IFN therapy. Antiviral Res. (1994) 24:235-244.
4. RAPPAPORT AM: In Diseases of the Liver. Schiff L, Schiff ER (Eds.) JB Lippincott Co., Philadelphia (1987):22.
5. GUYTON AC: Medical Physiology. 6th ed. W.B.SaundersCo.,(1981).
6. CENTERS FOR DISEASE CONTROL AND PREVENTION: Recommendations for the prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR (1998) 47 (no. RR19):indusive.
7. HOOFNAGLE JH, DI BISCEGLIE AM: The treatment of chronic viral hepatitis. Drug Therapy (1997') 336:347-356. • Review of currently available therapies for chronic viral hepatitis.
8. Drug Facts and Comparisons. OlinBR(Ed.), Facts and Comparisons, St. Louis, MO, (1996).
9. DAVIS GL: Current therapy for chronic hepatitis C. Gastroenterology (2000) 118:5104-5114.
10. ETO T, TAKAHASHI H: Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon. NatureMuL (1999) 5:577-581.
11. TABATA Y, MATSUIY, UNO K, SOKAWA Y, IKADA Y: Simple mixing of IFN with a polysaccharide having high liver affinity enables IFN to target to the liver./ Interferon Cytok'tneRfs. (1999) 19:287-292.
12. XI K, TABATA Y, UNO K et ai: Liver targeting of Interferon through pullulan conjugation. Pharm. Res. (1996) 13:18461850.
13. NOISAKRANS, CAMPBELL IL, CARR DJ: Ectopic expression of DNA encoding IFN-Ct 1 in the cornea protects mice from herpes simplex virus Type 1-induced encephalitis.J. ImmunoL (1999) 162:41844190.
14. NOISAKRANSJ, CARR DJ: Therapeutic efficacy of DNA encoding IFN-CC1 against corneal HSV-1 infection. Curr. Eye Rts. (2000) 20:405-4012.
15. YEOW WS, LAWSON CM, BEILHARZ MW: Antiviral activities of individual murine IFN-Ct subtypes in vivo: intramuscular injection of IFN expression constructs reduces cytomegalovirus replication. J. ImmunaL (1998) 160:2932-2939.
16. MONAHAN PE, SAMULSKIRJ, TAZELAARJ ttaL: Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther. (1998) 5:40-49.
17. HERZOG RW, YANG EY, COUTO LB et ai: Long-term correction of canine hemophilia B by gene transfer of blood coagulation Factor DC mediated by adenoassociated viral vector. Nature Med. (1999) 5:56-63.
18. AURISICCHIO L, DELMASTRO P, SALUCCIV ttaL: Liver-specific -a 2 Interferon gene expression results in protection from induced hepatitis.J. ViroL (2000)74:4816-4823.
19. PROTZER U, NASSAL M, CHIANG PW, KIRSCHFINK M, SCHALLER H: Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection. Proc. NatL Acad. Sei. USA (1999)96:10818-10823.
20. CHIOUHC, LUCAS MA, WUCCN aL: Long term expression and absence of murine immune response to human interferon after intravenous delivery to the liver by polyplex and formulants. MoL Ther. (2000)l(part2):S126.
21. GUIDOTTILG,ANDOK,HOBBSMV tt aL: Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. NatL Acad. Sei USA.(1994) 91:37643768.
22. LARKINJ.CLAYTONM.SUNB: Hepatitis B virus transgenic mouse model of chronic liver disease. Nature Med. (1999) 5:907-912.
23. GUIDOTTI LG, CHISARI FV: Cytokinemediated control of viral infections. Virology (2000) 273:221-227.
24. HUARD J, LOCHMULLER H, ACSADI G, JANI A, MASSIE B, KARPATI G: The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gent Thcr. (1995)2:107-115-
25. BENIHOUD K, YEH P, PERRICAUDET M: Adenovirus vectors for gene delivery. Curr. Of in. BiotechnoL (1999) 10:44047.
26. MONAHAN PE, SAMULSKI RJ: AAV veaors: is clinical success on the horizon? Gene Tber. (2000) 7:24-30.
27. ILAN Y, SAITO H, THUMMALA NR, CHOWDHURY NR: Adenovirusmediated gene therapy of liver diseases. Semin. Liver Dis. (1999) 19:49-59.
28. BREINER KM, URBAN S, GLASS B, SCHALLER H: Envelope protein-mediated down-regulation of hepatitis B virus receptor in infected hepatocytes.J. ViroL (2001)75:143-150.
29. LIAW YF: Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology(\y}5) 22:1101-1108.
30. LIAW YF, YEH CT, TSAI Sb Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am. J. GastrocnteroL (2000) 95:2978-2980.
31. CHENST, SU H.YEEJK: Repression of liver-specific hepatitis B virus enhancer 2 activity by adenovirus E1A proteins.J. ViroL (1992) 60:7452-7460.
32. SCHAACKJ.MAGUIREHKSIDDIQUI A: Hepatitis B virus X protein partially substitutes for E1A transcriptional function during adenovirus infection. Virology (1996) 216:425-i30.
33. • Study reports on interactions between HBV and adenovirus infections and the ability, in some specific cases, of a viral function from one species being able to complement a missing function from another.
34. PASTURE G, SANTANTONIO T, MONNO L, MILELLA M, LUCHENA N, ANGARANO G: Effects of HIV superinfection on HBV replication in a chronic HBsAg carrier with liver disease.J. HtpatoL (1988)7:164-168.
35. SCHLEHOFER JR, ZUR HAUSEN H: Adenovirus infection induces amplification of persistent viral DNA sequences (simian virus 40, hepatitis B virus, bovine papillomavirus) in human and rodent cells. Virus Res. (1990)17:53-60.
36. ZEUZEMS.FEINMANSV.RASENACK J étal.: Peginterferon a!fa-2a in patients with chronic hepatitis C. N. EngL J. Med. (2000) 343:1666-1672.
37. HEATHCOTE EJ, SHIFFMAN ML, COOKSLEY WG etaL: Pcginterferon alfa2a in patients with chronic hepatitis C and cirrhosis. N. Eng.]. Med. (2000) 343:16731680.
38. GLUE P, FANG JW, ROUZIER-PANIS R etaL: Pegylated interferon-al2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin. PharmacoL Ther. (2000) 68:556-567.
39. WANGL,TAKABEK,BIDLINGMAIER SM, ILL CR, VERMA IM: Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc. NatLAcad. Sei. USA (1999) 96:3906-3910.
40. SCAGLIONIPP, MELEGARIM, WANDS JR: Characterization of hepatitis B virus core mutants that inhibit viral replication. Vm%y (1994) 205:112-120.
41. SCAGLIONI P, MELEGARI M, TAKAHASHI M, CHOWDHURYJR, WANDS J: Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology (1996) 24:1010-1017.
42. VON WEIZSÄCKERF, WIELAND S, BLUM HE: Inhibition of viral replication by genetically engineered mutants of the duck hepatitis B virus core protein. //<•/%-(1996) 24:294-299.
43. •• Demonstration that expression of a modified core protein, exhibiting a dominant negative phenotypc, can inhibit hepadnaviral virion production by inhibition of nucleocapsid formation. The
44. authors propose that expression of this type of mutant protein could be employed as an anti-HBV gene therapy.
45. LARAS A, KOSKINAS J, AVGIDIS KHADZIYANNIS SJ: Incidence and clinical significance of hepatitis B virus precorc gene translation initiation mutations in c antigen-negative patients. J. Viral Hepatitis (1998) 5:241-248.
46. LINDH M, HORAL P, DHILLON AP, NORKRANS G: Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B.J. Viral Hepatitis (2000) 7:258-267.
47. BUCKWOLDVE,XUZ,CHENM,YEN TS, OU JH: Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication.J. VtroL (1996) 70:58455851.
48. SCAGLIONIPP, MELEGARI M, WANDS JR: Posttranscriptional regulation of hepatitis B virus replication by the precore protein.J. ViroL (1997)71:345353.
49. GUIDOTI LG, MATZKE B, PASQUINELLI C, SHOENBERGERJM, ROGLER CE, CHISARIFV: The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice.J. ViroL (1996) 70:7056-7061.
50. CHISARI FV: Hepatitis B virus transgenic mice: insights into the virus and the disease. Hepato!ogy(l995) 22:1316-1325.
51. RUIZ J, QIAN C, DROZDZIK M, PRIETO J: Gene therapy of viral hepatitis and hepatocellular carcinoma.J. Viral Hepatitis (1999) 6:17-34.
52. VON WEIZSÄCKERF, WIELANDS, KOCKJ et al.: Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology (1997) 26:251-255.
53. CASELMANNWH.EISENHARDTS, ALT M: Synthetic antisense oligodeoxynucleotides as potential drugs against hepatitis C. Inttrvirology (1997) 40:394-399.
54. MONTEITH DK, LEVIN AA: Synthetic oligonucleotides: the development of antisense therapeutics. ToxicoL PathoL (1999) 27:8-13.
55. • Summary of pharmacokinetics and toxicities of phosphorothioate oligonucleotides.
56. SOMIAN.VERMA IM: Gene therapy: trials and tribulations. Nature Rev. (2000) 1:91-99.
57. HAN S, MAHATO RI, SUNG YK, KIM SW: Development of biomaterials for gene therapy. Mol Ther. (2000)2:302-317.
58. LUOD.SALTZMANWM: Synthetic DNA delivery systems. Nature BiotechnoL (2000) 18:33-37.
59. DE SMEDT SC, DEMEESTERJ, HENNINK WE: Cationic polymer based gene delivery systems. Pharmaceut. Res. (2000)17:113-126.
60. SMITH LC, DUGUID J, WADHWA MS et ai: Synthetic peptide-based DNA complexes for nonviral gene delivery. Adv. DrugDeliv. Rev. (1998) 30:115-131.
61. BOUSSIF O, LEZOUALCH F, ZANTA MA ftaL:A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo-, polyethylenimine. Proc. NatL Acad. Sei. USA (1995) 92:7297-7301.
62. KABANOV AV, KABANOV VA: Interpolyelectrolyte and block ionomer complexes for gene delivery: physicochemical aspects. Adv. DrugDeliv. Rev. (1998)30:49-60.
63. PLANK C, TANG MX, WOLFE AR, SZOKA PCJR: Branched cationic peptides for gene delivery: role of type and number of cationic residues in formation and in vitro activity of DNA polyplexes. Hum. Gene Ther. (1999) 10:319-332.
64. COLLARD WT, YANG Y, KWOK KY, PARKY, RICE KG: Biodistribution, metabolism, and in vivo gene expression of low molecular weight glycopeptide polyethylene glycol peptidc DNA cocondensates.J. Pharm. Sei. (2000) 89:499. 512.
65. MACLAUGHLIN FC, MUMPER RJ, WANG J etal: Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery.J. Control Rtltasc (1998) 56:259272.
66. KUKOWSKA-LATALLO JF, BIELINSKA AU, JOHNSON], SPINDLER R, TOMALIA DA, BAKER JR: Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. Proc. NatL Acad. Sei. USA (1996) 93:4897-4902.
67. ZUIDAMNJ, POSTHUMA G, DE VRIES ET, CROMMELIN DJ, HENNINK WE, STORM G: Effects of physicochemical characteristics of poly(2(dimethylamino)ethyl methacrylate)-based polyplexes on cellular association and internalization.J. Drug Target (2000) 8:5166. (A. OUPICKY D, KONAK C, ULBRICH K, WOLFERT MA, SEYMOUR LW: DNA delivery systems based on complexes of DNA with synthetic polycations and their copolymers.y. ControlltdRelease(2000) 65:149-171.
68. LOLLO CP, BANASZCZYK MG, CHIOU HC: Obstacles and advances in non-viral gene delivery. Curr, Of in. MoL Thtr. (2000) 2:136-142.
69. MIR LM, BUREAU MF, GEHL Jetai: High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc. NatL Acad. Sei. USA (1999) 96:4262-7.
70. AIHARAH.MIYAZAKIJ: Gene transfer into muscle by clcctroporation in vivo. Nature BiotechnoL (1998) 16:867-870.
71. LJU F, SONG YK, LIU D: Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. (1999) 6:12581266.
72. ZHANG G, BUDKER V, WOLFF JA: High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum. Gene Ther. (1999) 10:1735-1737.
73. BUDKER V, ZHANG G, DANKO I, WILLIAMS P, WOLFF J: The efficient expression of imravascularly delivered DNA in rat muscle. Gent Thfr. (1998) 5:272-276.
74. LAWRIE A, BRISKEN AF, FRANCIS SE et ai: Ultrasound enhances reporter gene expression after transfection of vascular cells in vitro. Circulation (1999) 99:2617-2620.
75. VONDERLEYENHE.BRAUN-DULLAEUS R, MANN MJ, ZHANG L, NIEBAUER J, DZAU VJ: A pressuremediated nonviral method for efficient arterial gene and oligonucleotide transfer. Hum. Cent Thtr. (1999) 10:2355-2364.
76. KURIYAMAN.KURIYAMAH.JULIN CM, LAMBORN K, ISRAEL MA: Pretreatment with protease is a useful experimental strategy for enhancing
77. adenovirus-mediated cancer gene therapy. Hum. Gene Ther. (2000) 11:2219-2230.
78. MAILLARD L, ZIOL M, TAHLIL O rf Z: Pre-treatment with elastase improves the efficiency of percutaneous adenovirusmediated gene transfer to the arterial media. Gene Ther. (1998) 5:1023-1030.
79. LEGENDRE JY, TRZECIAK A, BOHRMANN B, DEUSCHLE U, KITAS E, SUPERSAXO A: Dioleoylmelittin as a novel serum-insensitive reagent for efficient transfection of mammalian cells. Bioconjug. Chem. (1997) 8:57-63.
80. WAGNER E: Application of membraneactive peptides for nonviral gene delivery. Adv. DrugDelm Rev. (1999) 38:279-289.
81. DANKO I, FRITZ JD, JIAO S, HOGAN K, LATENDRESSE JS, WOLFF JA: Pharmacological enhancement of in vivo foreign gene expression in muscle. Gene Ther. (1994) 1:114-121.
82. CROYLEMA,ROESSLERBJ,HSUCP, SUN R, AMIDON Gb Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine. Pharmiceut. Res. (1998)
83. FREEMAN DJ, NIVEN RW: The influence of sodium glycocholate and other additives on the in vivo transfection of plasmid DNA in the lungs. Pharmaceut. Res. (1996) 13:202-209.
84. ROSS GF, MORRIS RE, CIRAOLO G et ai: Surfactant protein A-polylysine conjugates for delivery of DNA to airway cells in culture. Hum. Gene Ther. (1995) 6:31-40.
85. MALIK AH, LEE WM: Chronic hepatitis B virus infection: treatment strategies for the next millennium. Ann. Intern. Med. (2000) 132:723-731-